Our strategic partnerships in academic medicine

Research at SingHealth is built on the strong partnership we have with our partner in academic medicine, Duke-NUS Medical School. Together, we offer potential collaborators our expertise from bench to bedside.


Our established relationship with Duke-NUS and its parent school, Duke North Carolina (USA), has also led to memoranda of understanding for greater global collaboration among our core platforms. SingHealth’s Investigational Medicine Unit (IMU), the largest public sector unit dedicated to early phase clinical trials, has an established relationship with Duke University’s Clinical Research Unit in North Carolina, USA, and its investigational medicine unit in Medanta, India, to facilitate appropriate multi-site studies. One project that has already been initiated is a study to investigate microarray signatures to aspirin response.


We also closely collaborate with other leading academic institutions and national agencies:

  • Agency for Science, Technology and Research (A*Star)
  • Bioinformatics Institutes (BII)
  • Biomedical Sciences Institutes (BSI)
  • Genome Institute of Singapore (GIS)
  • Institute for Infocomm Research (I2R)
  • Institute of Bioengineering and Nanotechnology (IBN)
  • Institute of Medical Biology (IMB)
  • Institute of Molecular and Cell Biology (IMCB)
  • Institute of Technical Education (ITE)
  • Nanyang Polytechnic (NYP)
  • Nanyang Technological University (NTU)
  • National University of Singapore (NUS)
  • National University Hospital (NUH)
  • Ngee Ann Polytechnic (NP)
  • Singapore Institute for Clinical Science (SICS)
  • Singapore Institute of Manufacturing Technology (SIMtech)


  • John Hopkins University
  • National Human Genome Research Institute
  • Stanford University

Established collaborations

Apart from our strategic partnership with Duke-NUS, our two academic campuses at Singapore General Hospital (SGH) and KK Women's & Children's Hospital (KKH) are home to a great number of collaborators from industry and academic organisations.

One of the recent additions is a nationwide collaboration in stratified medicine. SingHealth institutions – SGH, National Cancer Center Singapore (NCCS) and Singapore National Eye Centre (SNEC) – are key clinical partners to the Genome Institute of Singapore (GIS), an institution under the Agency for Science, Technology and Research (A*Star), which is driving the national effort to realise the potential of stratified medicine in diseases relevant to the region, such as gastric and lung cancer, and eye diseases. The Personalised OMIC Lattice for Advanced Research and Improving Stratification (POLARIS) initiative will provide opportunities to evaluate new drug candidates and biomarkers that are relevant to the growing Asian patient population.

SingHealth institutions have also established translational and clinical research partnerships with:

  • Astra-Zeneca
  • Bayer
  • Boehringer Ingelheim
  • Eisai
  • Fibrogen
  • GlaxoSmithKline (GSK)
  • MSD
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Sirtex
  • Takeda/Millenium
  • Eli Lilly
  • Carl Zeiss Meditech


In addition, SingHealth IMU is a recognised site for the conduct of early phase trials by the Health Sciences Authority of Singapore (HSA).